WO2026038151 - USE OF GPR119 AGONISTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS
National phase entry is expected:
Publication Number
WO/2026/038151
Publication Date
19.02.2026
International Application No.
PCT/IB2025/058211
International Filing Date
12.08.2025
Title **
[English]
USE OF GPR119 AGONISTS FOR THE TREATMENT OF METABOLIC-RELATED DISORDERS
[French]
UTILISATION D'AGONISTES DE GPR119 POUR LE TRAITEMENT DE TROUBLES LIÉS AU MÉTABOLISME
Applicants **
MANKIND PHARMA LTD.
Inventors
PANWAR, Amit
KHAN, Mohd. Imran
RAI, Santosh Kumar
KUMAR, Anil
Priority Data
202411061620
14.08.2024
IN
Application details
| Total Number of Claims/PCT | * |
| Number of Independent Claims | * |
| Number of Priorities | * |
| Number of Multi-Dependent Claims | * |
| Number of Drawings | * |
| Pages for Publication | * |
| Number of Pages with Drawings | * |
| Pages of Specification | * |
| * | |
| Number of Office Actions | * |
| * | |
International Searching Authority |
EPO
* |
| Recordal of a Change of the Applicant's Name/Address |
Change of Applicant's Name and Address
* |
| Type of Assignment |
The Standard Agent's Assignment
* |
| Applicant's Legal Status |
Legal Entity
* |
| * | |
| * | |
| * | |
| * | |
| * | |
| Entry into National Phase under |
Chapter I
* |
| Patent Delivery |
Send the Letters Patent by Courier
* |
| 译文 |
|
* The data is based on automatic recognition. Please verify and amend if necessary.
** IP-Coster compiles data from publicly available sources. If this data includes your personal information, you can contact us to request its removal.
Quotation for National Phase entry
| Country | Stages | Total | |
|---|---|---|---|
| China | Filing, Examination, Granting | 2171 | |
| EPO | Filing, Examination, Granting | 10656 | |
| Japan | Filing, Examination, Granting | 2307 | |
| South Korea | Filing, Examination, Granting | 2380 | |
| USA | Filing, Examination, Granting | 4740 |
Total:
22,254
Contact Us
Abstract[English]
This disclosure relates to the use of GPR119 agonists for the treatment and/or prevention of metabolic-related diseases and disorders, such as non-alcoholic fatty liver disease (NAFLD) and non-alcoholic steatohepatitis (NASH).[French]
La présente divulgation concerne l'utilisation d'agonistes de GPR119 pour le traitement et/ou la prévention de maladies et de troubles liés au métabolisme, tels que la stéatose hépatique non alcoolique (NAFLD) et la stéatohépatite non alcoolique (NASH).